IB Net Payout Yields Model

Invest like me - only at Covestor.com

AMD: Not The $4 Billion Reasons To Own

By -

 

  • AMD announced a $4 billion share buyback cheered by the market, yet only amounting to 3% of the combined company once adding Xilinx.
  • The combined company expects billions in additional revenue by 2023 in comparison to when the merger was announced just in October.
  • The stock is cheap as 2022 EPS estimates start pushing toward $3.
  • This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Learn More »

Now that Advanced Micro Devices (AMD) has dispelled the Intel (INTC) risks in the near term, investors can return to focusing on the long-term growth story of the chip company. The recent dip into the low $70s provided an opportune time for new investors to invest in this story alongside the company. My investment thesis remains highly bullish on the stock.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Update - June 2

Just another reason to own AMD. SemiAccurate has the chip company taking the lead in advanced packing due to their new 3D V-Cache product. 

-AMD just vaulted back into the advanced packaging lead last night with their 3D V-Cache technology. SemiAccurate will try to explain why this is several steps beyond what others have done or even shown off.

The stock continues to hold support just below $75, but AMD hasn't broken the downtrend yet. 

Finviz Chart

Update - July 8

Boom times! GS should've issued a $150 PT with that '23 EPS estimate. The Chinese review of the Xilinx deal isn't a reason to sell AMD. 

-Thinking the Street is underestimating AMD's (NASDAQ:AMD) near- and long-term revenue growth and margin expansion potential, Goldman Sachs raises its price target from $106 to $111. The firm reiterates a Buy rating and AMD's place on its conviction buy list.

-Goldman estimates non-GAAP EPS of $3.81 for 2022 and $5.48 for 2023, 41% and 64% above consensus, respectively.

Popular posts from this blog

Occidental: Still Producing Too Much Oil

By -
Image
Though oil continues plunging, the oil giants continue producing more. For Q4, Occidental Petroleum (OXY) had roughly flat production. The worst part is that OXY plans to grow production by 2% to 4% in 2016. The stock has held up somewhat strong, but the inability to turn off the spigot remains troubling. Disclosure: No positions mentioned. Please review the disclaimer page for more details. 
Read more

ChargePoint: Low Quality Beat

By -
Image
  ChargePoint beat FQ2'22 revenue estimates, but the losses are mounting. The company guided up FY22 numbers partly due to acquisitions. The stock still trades at an estimated 21x FY23 number leaving limited upside for the stock and reinforcing why venture funds sold 13.8 million shares. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio.  Learn More » After  solid FQ2'22 earnings ,  ChargePoint Holdings  ( CHPT ) has seen a nice bump in the stock. Now investors have to confront the valuation divide and deal with the past insider sales likely leading to future sales on any stock rallies. My  investment thesis  remains very Bearish on the EV charging station stock on any rallies into the mid-$20s. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer page for more details.  Update - Sept. 8 Be cautious when analysts struggle to make the bullish case on expen
Read more

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more